Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 11/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22677493 | 1.00 | MME (0.49) | MMEMMEL1ACEACE2LTA4H | |
| SCHEMBL18078113 | 1.00 | MME (0.49) | MMEMMEL1ACEACE2LTA4H | |
| SCHEMBL24595272 | 1.00 | MME (0.49) | MMEMMEL1ACEACE2LTA4H | |
| SCHEMBL22677474 | 0.93 | MME (0.45) | MMEMMEL1ACE | |
| SCHEMBL21377698 | 0.93 | MME (0.45) | MMEMMEL1ACE | |
| SCHEMBL19872227 | 0.93 | MME (0.45) | MMEMMEL1ACE | |
| SCHEMBL18078117 | 0.93 | MME (0.45) | MMEMMEL1ACE | |
| SCHEMBL24058545 | 0.91 | MME (0.43) | MMEMMEL1ACELTA4H | |
| SCHEMBL19969264 | 0.89 | ACE (0.46) | MMEMMEL1ACEACE2LTA4H | |
| SCHEMBL19969548 | 0.89 | ACE (0.46) | MMEMMEL1ACEACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379024-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | AURIGENE ONCOLOGY LIMITED (IN) | 2021-12-09 | — | — | US | disclosed |
| US-20200361880-A1 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| US-10781189-B2 | 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-09-22 | — | — | US | disclosed |
| US-20180044303-A1 | 1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379024-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | PDCD1, CD274, PDCD1LG2 | MME 4624/4885MMEL1 1822/4885ACE 3328/4885 |
| US-10781189-B2 | 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators | PDCD1, PDCD1LG2, CD274 | MME 4758/4885MMEL1 825/4885ACE 3938/4885 |
| US-20200361880-A1 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | PDCD1, CD274, PDCD1LG2 | MME 4804/4885MMEL1 830/4885ACE 3762/4885 |
| US-20180044303-A1 | 1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, PDCD1LG2, CD274 | MME 4758/4885MMEL1 825/4885ACE 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.